What the business is, and whether it's a good one at a fair price.
Makes specialty chemicals across four segments, with pharmaceutical intermediates the dominant business. Pharma intermediates contributed 87.7% of FY26 revenue (₹11,741 Mn), supplying advanced intermediates and CDMO products to global pharmaceutical customers; the segment grew 76.5% YoY in Q1 FY27 to ₹292.7 cr. Commodity chemicals accounted for 11.2% of FY26 revenue and are being deliberately phased out as lower-margin products are replaced by higher-margin specialty offerings. Semiconductor chemicals — where the company is India's only photoresist manufacturer — made up 1.2% of FY26 revenue, with a new IndiChem plant in Korea due to start commercial revenue from FY28. Battery chemicals commercial supply commenced in Q1 FY27 after trial runs, targeting full 4,000 MT capacity (2,000 MT VC + 2,000 MT FEC) within three years. The cost base is dominated by raw materials at 44.4% of FY26 revenue, with capex at 24.5% reflecting heavy capacity expansion across plants. Management has guided to 25% revenue growth for FY27 with stable margins.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from ACUTAAS CHEMICALS LIMITED's filed financials and exchange disclosures
ACUTAAS CHEMICALS LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ACUTAAS.
Yes. Over the trailing twelve months ACUTAAS CHEMICALS LIMITED reported a net profit of ₹387 Cr on revenue of ₹1,462 Cr.
Yes. The dividend yield is 0.04% at the current price. It paid out 3% of its profit as dividend in FY26.
Effectively yes. It holds ₹189 Cr more cash than debt. Debt stands at 0.02× equity.
On trailing P/E, ACUTAAS CHEMICALS LIMITED ranks 145 of 169 in Pharmaceuticals — cheaper than 14% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session ACUTAAS CHEMICALS LIMITED moves 1.48% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by ACUTAAS CHEMICALS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
